Altamira Therapeutics (CYTO) Provides Update on Nasdaq Listing Oct 4, 2024 04:01PM
Altamira Therapeutics (CYTO) Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray Sep 27, 2024 09:01AM
Altamira Therapeutics (CYTO) Prices $12M Offering at $0.72/sh Sep 17, 2024 05:01PM
Altamira Therapeutics (CYTO) Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia Sep 16, 2024 08:31AM
Altamira Therapeutics (CYTO) Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark Aug 23, 2024 09:01AM


Aug 16, 2024 09:01AM Altamira Therapeutics (CYTO) Announces Confirmed Suitability of Bentrio for Athletes
Aug 12, 2024 09:03AM Altamira Therapeutics (CYTO) Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles
Jul 19, 2024 09:01AM Altamira Therapeutics (CYTO) Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Jun 20, 2024 09:02AM Altamira Therapeutics (CYTO) Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management